NASDAQ:MBRX
Moleculin Biotech, Inc.
- Stock
Last Close
0.46
06/11 22:12
Market Cap
7.84M
Beta: 2.00
Volume Today
106.76K
Avg: 244.71K
PE Ratio
−0.62
PFCF: −0.65
Preview
Full access to financials is available to subscribers only. Please support our work and get full access to all features. You can cancel anytime. If you'd like a demo, free trial or have any questions, please checkout the help page
Dec '15 | Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | ||
|---|---|---|---|---|---|---|---|---|---|---|
average inventory | 1.10M - | 2.03M 84.20% | 907.50K 55.39% | -33.50K 103.69% | -11K 67.16% | |||||
average payables | 405K - | 1.03M 153.83% | 1.70M 65.32% | 1.64M 3.44% | 1.25M 24.04% | 3.09M 148.01% | 3.66M 18.34% | |||
average receivables | 5.50K - | 6K 9.09% | 23K 283.33% | 33.50K 45.65% | 60.50K 80.60% | |||||
book value per share | 9.13 - | 5.53 39.44% | 3.31 40.23% | 2.29 30.60% | 1.80 21.38% | 2.94 62.94% | 1.82 37.92% | 13.20 623.31% | ||
capex per share | -0.01 - | -0.01 30.98% | -0.10 967.58% | -0.01 92.07% | -0.04 398.44% | -0.00 98.15% | -0.00 231.32% | -0.06 2,579.65% | ||
capex to depreciation | -3.48 - | -1.56 55.35% | -6.13 294.22% | -0.26 95.74% | -1.88 619.46% | -0.12 93.84% | -0.52 344.86% | -0.98 89.45% | ||
capex to operating cash flow | 0.01 - | 0.00 32.96% | 0.03 793.84% | 0.00 91.15% | 0.02 599.76% | 0.00 95.26% | 0.00 141.79% | 0.01 112.24% | ||
capex to revenue | ||||||||||
cash per share | 3.06 - | 2.49 18.47% | 1.65 33.71% | 1.58 4.28% | 1.54 2.57% | 2.64 71.19% | 1.51 42.83% | 11.92 690.30% | ||
days of inventory on hand | ||||||||||
days payables outstanding | 7.18K - | |||||||||
days sales outstanding | ||||||||||
debt to assets | 16.02 - | 0.02 99.89% | 0.02 - | 0.01 36.47% | 0.00 80.18% | 0.01 315.38% | 0.02 91.23% | |||
debt to equity | -0.60 - | 0.02 103.28% | 0.02 - | 0.02 35.92% | 0.00 87.09% | 0.01 329.31% | 0.02 154.77% | |||
dividend yield | ||||||||||
earnings yield | -0.18 - | -0.28 62.01% | -0.44 55.28% | -0.35 19.61% | -0.32 10.09% | -0.18 44.38% | -0.90 410.05% | -1.17 29.41% | ||
enterprise value | 421.91K - | 17.70M 4,094.26% | 26.82M 51.59% | 19.81M 26.16% | 26.90M 35.84% | 32.17M 19.56% | -20.75M 164.52% | -12.37M 40.38% | 2.47M 119.96% | |
enterprise value over ebitda | -4.56 - | -3.58 21.46% | -1.09 69.66% | -1.26 15.66% | -1.47 16.82% | 0.70 147.82% | 0.39 44.94% | -0.08 121.63% | ||
ev to operating cash flow | -4.70 - | -3.66 22.08% | -1.62 55.68% | -1.56 3.62% | -1.81 15.70% | 1.10 160.51% | 0.45 59.12% | -0.10 122.89% | ||
ev to sales | ||||||||||
free cash flow per share | -2.31 - | -2.38 2.76% | -2.92 23.05% | -2.54 13.05% | -1.84 27.48% | -0.71 61.70% | -0.97 37.23% | -12.26 1,165.97% | ||
free cash flow yield | -0.17 - | -0.21 25.97% | -0.47 120.07% | -0.46 1.17% | -0.39 16.71% | -0.38 1.59% | -0.91 140.79% | -0.95 4.19% | ||
graham net net | 2.18 - | 1.73 20.81% | 0.42 75.60% | 0.32 23.71% | 0.49 52.55% | 2.45 398.92% | 1.33 45.87% | 5.81 338.35% | ||
graham number | 22.20 - | 19.86 10.54% | 14.30 27.96% | 10.02 29.94% | 7.86 21.55% | 4.67 40.61% | 6.27 34.33% | 66.89 966.49% | ||
income quality | 0.96 - | 0.75 22.10% | 1.03 37.56% | 1.30 26.75% | 1.02 21.38% | 1.19 16.44% | 0.95 20.14% | 0.81 14.98% | ||
intangibles to total assets | 0 - | 0.68 Infinity% | 0.57 15.86% | 0.57 0.52% | 0.44 22.39% | 0.38 13.08% | 0.13 65.48% | 0.19 46.44% | 0.29 50.25% | |
interest coverage | -89.86 - | 18.97 - | ||||||||
interest debt per share | 0.21 - | 0.06 - | 0.03 49.62% | 0.01 78.97% | -0.04 787.84% | 0.29 813.99% | ||||
inventory turnover | ||||||||||
invested capital | -0.60 - | 0.02 103.28% | 0.02 - | 0.02 35.92% | 0.00 87.09% | 0.01 329.31% | 0.02 154.77% | |||
market cap | 22.41M - | 34.54M 54.14% | 26.94M 22.00% | 37.26M 38.31% | 47.06M 26.31% | 49.99M 6.22% | 30.32M 39.35% | 25.45M 16.08% | ||
net current asset value | -744.70K - | 3.79M 608.89% | 5.94M 56.66% | 2.66M 55.18% | 3.82M 43.56% | 5.93M 55.16% | 67.40M 1,037.17% | 40.37M 40.11% | 14.13M 65.00% | |
net debt to ebitda | 1.22 - | 1.03 15.16% | 0.39 62.00% | 0.48 23.60% | 0.68 40.55% | 2.40 251.99% | 1.34 44.26% | 0.78 41.68% | ||
net income per share | -2.40 - | -3.17 32.16% | -2.75 13.17% | -1.95 29.27% | -1.52 21.72% | -0.33 78.36% | -0.96 190.67% | -15.07 1,472.49% | ||
operating cash flow per share | -2.30 - | -2.37 2.95% | -2.83 19.44% | -2.53 10.35% | -1.80 28.77% | -0.71 60.93% | -0.97 37.03% | -12.20 1,162.54% | ||
payables turnover | 0.05 - | |||||||||
receivables turnover | ||||||||||
research and ddevelopement to revenue | ||||||||||
return on tangible assets | -0.75 - | -1.18 57.16% | -1.41 19.66% | -0.94 33.41% | -0.84 10.54% | -0.12 85.51% | -0.59 387.66% | -1.10 85.66% | ||
revenue per share | ||||||||||
roe | -0.26 - | -0.57 118.25% | -0.83 45.27% | -0.85 1.91% | -0.84 0.43% | -0.11 86.72% | -0.53 368.24% | -1.14 117.40% | ||
roic | -0.25 - | -0.56 121.94% | -1.33 135.72% | -1.05 20.78% | -0.93 11.70% | -0.16 82.67% | -0.55 238.34% | -1.09 100.03% | ||
sales general and administrative to revenue | ||||||||||
shareholders equity per share | 9.13 - | 5.53 39.44% | 3.31 40.23% | 2.29 30.60% | 1.80 21.38% | 2.94 62.94% | 1.82 37.92% | 13.20 623.31% | ||
stock based compensation to revenue | ||||||||||
tangible asset value | -744.70K - | 3.81M 612.00% | 5.97M 56.58% | 3.12M 47.67% | 4.42M 41.58% | 6.61M 49.49% | 67.84M 926.09% | 41.04M 39.50% | 14.93M 63.64% | |
tangible book value per share | 2.33 - | 1.93 17.13% | 0.72 62.49% | 0.65 9.94% | 0.67 3.05% | 2.52 275.90% | 1.43 43.16% | 7.55 426.51% | ||
working capital | -744.70K - | 3.88M 620.64% | 6.09M 56.99% | 4.10M 32.71% | 9.91M 142.04% | 14.28M 44.02% | 68.88M 382.39% | 40.78M 40.80% | 19.46M 52.28% |
All numbers in USD (except ratios and percentages)